Glycoprotein engineering is the part of antibody discovery and protein engineering where the choice of expression host stops being a workflow preference and becomes a hard constraint. Yeast cannot install mammalian-complex N-glycans. E. coli cannot install N-glycans at all. For targets whose biology depends on those glycans — and for antibody Fc engineering where effector function is the deliverable — the campaign has to be built around mammalian cells from the start.
This article is the decision framework for when glycosylation forces you out of yeast display and into mammalian, plus a quick survey of the glycoengineering tools that the field uses to install specific glycan profiles.
What N-glycosylation actually does
N-linked glycosylation isn’t ornamental. The glycan chain on an Asn-X-Ser/Thr motif contributes to:
- Protein folding and stability. The high-mannose precursor (Man9-GlcNAc2) is a quality-control signal in the ER; glycoproteins are retained for refolding until the signal is processed correctly.
- Half-life in circulation. Sialylated complex glycans extend serum half-life by masking the asialoglycoprotein receptor on hepatocytes. Desialylated glycoproteins are cleared rapidly.
- Receptor binding and signaling. Many cell-surface receptors require their N-glycans for ligand interaction. The IgG Fc-FcγR interaction is the canonical example.
- Effector function. Antibody Fc fucosylation status dictates ADCC potency; afucosylated antibodies show 10–100× enhanced ADCC.
- Immunogenicity. Non-human glycans (yeast high-mannose, plant xylose, α-galactose) are immunogenic in humans. Therapeutic biologics must avoid them.
The glycan is part of the molecule’s biology. Engineering the protein without engineering (or at minimum specifying) the glycan is incomplete.
Yeast glycosylation — high-mannose only
S. cerevisiae and P. pastoris install glycans through the same ER pathway as mammalian cells up to the Man9-GlcNAc2 precursor. Then the pathways diverge. Yeast Golgi enzymes extend the mannose chain into hyperglycosylated high-mannose structures (Man20+ for S. cerevisiae, Man8-Man15 for P. pastoris). Mammalian Golgi enzymes trim mannose and add complex glycans.
For a yeast-displayed antibody discovery campaign, two consequences:
- The displayed antibody itself is hyperglycosylated. If the antibody has N-glycosylation sites near the binding interface, those sites carry yeast-style mannose during display but will carry complex glycans in mammalian production. Apparent affinity on yeast and final affinity in production may differ.
- The target, if displayed against, is yeast-style if produced in yeast. Antibodies selected against yeast-produced glycoprotein target may not bind the mammalian-produced version. This is the larger concern.
For pure protein-epitope targets (no glycan involvement in the binding mode), yeast display works fine. For glycan-involving targets, yeast is the wrong host.
Mammalian glycosylation — CHO vs HEK profiles
Two production hosts dominate, with different glycan profiles.
CHO installs complex biantennary N-glycans with low sialylation (most CHO lines produce mostly α2,3-sialylation, less α2,6 than human cells). High core fucosylation is the default. Galactosylation is moderate. The glycan profile is well-characterized and regulatory authorities are familiar with it.
HEK293 installs complex N-glycans closer to native human — higher sialylation, both α2,3 and α2,6 linkages present, lower core fucosylation than CHO. Useful for research-grade antibodies that need human-like glycosylation, but HEK is rarely the production host for therapeutic biologics.
Neither host installs identical glycans to those a human cell would. The differences are typically small and clinically tolerable, but glycoengineered variants of both hosts exist (see below) when specific glycan profiles are required.
When the campaign needs mammalian display from the start
The decision criteria:
Target is a glycoprotein with glycan-dependent epitopes. Examples: complement components, mucin-domain proteins, glycan-specific therapeutic targets (sialyl-Lewis X for cancer, GD2 for neuroblastoma, blood group antigens). Yeast-displayed antibodies will miss these epitopes systematically.
The antibody format is full-length IgG. Yeast can’t display full IgG efficiently. If the program is post-discovery and needs full IgG validation, mammalian is the right host.
Effector function is part of the deliverable. ADCC, CDC, or ADCP potency depends on Fc glycosylation. Engineering for these activities requires mammalian production from the start, ideally in glycoengineered host lines.
Late-stage developability validation. Even for non-glycoprotein targets, the mammalian production glycoform is what reaches the clinic. Validating developability in mammalian cells catches issues yeast can’t predict.
If none of these conditions apply, yeast display is fine. Run yeast for discovery; validate in mammalian downstream as part of the two-platform workflow. If any apply, mammalian display from round one. We covered the platforms in mammalian cell display: CHO and HEK293.
Engineering tools — glycoengineering CHO lines
When a defined glycan profile is the deliverable, the host cell line itself is engineered:
Afucosylated lines (FUT8 KO). Knockout of α1,6-fucosyltransferase eliminates core fucose. Antibodies produced in these lines show 10–100× higher ADCC potency. Commercial lines: GlycArt (Roche/Glycart-style), Potelligent (BioWa), Glymaxx. Used for clinical antibodies targeting solid tumors.
Bisected GlcNAc lines (GnTIII overexpression). Adds a bisecting N-acetylglucosamine that also enhances ADCC. Less dramatic effect than fucosylation removal but pairs with it.
Galactosylation engineering. β1,4-galactosyltransferase overexpression increases terminal galactose content. Relevant for biosimilar matching to innovator glycan profiles.
Sialylation engineering. α2,6-sialyltransferase knock-in delivers more human-like sialylation. Used when the program targets the FcRn-mediated half-life or anti-inflammatory IgG (IVIG-like) activity that requires sialylated Fc.
Mannose receptor avoidance. Engineered to avoid high-mannose contamination from incomplete processing — relevant for biologics where mannose-receptor-mediated clearance shortens half-life.
For most clinical antibody programs, the host is either an off-the-shelf CHO line or one of the established glycoengineered variants (Potelligent for ADCC, BioWa for bisecting glycans). For research-grade work, HEK293 with its more human-like glycosylation is often sufficient.
Practical workflow for glycoprotein engineering
For a target where glycosylation matters:
- Define the glycan profile target. Specific glycoforms? Avoid certain glycans? Match an innovator? The downstream host choice depends on this.
- Source target antigen from mammalian cells. Yeast-produced or E. coli-produced antigen for selection is a false economy if the production target is glycosylated.
- Build the antibody library in mammalian display from the start. CHO or HEK293 depending on stage; engineered host lines if specific glycoforms are required.
- Counter-select against alternative glycoforms. During sorting, include negative selection against the unwanted glycoform to enrich for glycan-specific binders.
- Validate in production-relevant host. Confirm the final lead’s binding mode and effector function match expectations in the production line.
The cost premium of mammalian-only vs yeast-led discovery is 2–4× in screening cost and 1.5–2× in wall-clock. For glycoprotein-relevant programs, the cost is the price of getting the right answer.
Decision summary
If the target involves glycan-dependent epitopes, or the antibody format is full-length IgG, or effector function is a deliverable: skip yeast and go to mammalian display from round one.
If glycoengineering is required (afucosylation, defined sialylation, bisecting GlcNAc): use an engineered CHO line as the production host and run mammalian display in the same line.
If the target is a soluble protein with no glycan dependence and the antibody format is scFv or VHH: yeast display is the right discovery platform; mammalian display joins the workflow downstream for developability validation.
If you’re scoping a glycoprotein engineering or PTM-dependent target program, see our mammalian display services or reach out via the contact page. For combined yeast-and-mammalian workflows, see the AI Binder Sprint.
Related Ranomics services
- Mammalian display: CHO and HEK293 display platforms for glycoprotein and PTM-dependent targets.
- Cell engineering: Glycoengineered CHO line development.
- AI Binder Sprint: Multi-platform programs covering glycoprotein targets end-to-end.